Exenatide
The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients
AstraZeneca · Phase 3 · Terminated · Enrollment 13
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Dapagliflozin plus Exenatide | n/r | n/r | n/r | n/r | n/r |
| Placebo plus Placebo | n/r | n/r | n/r | n/r | n/r |
| Placebo plus Exenatide | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.